768378-07-0

Basic information

• Product Name: tert-butyl 2-(4-tert-butylphenoxy)acetate
• Synonyms: tert-butyl 2-(4-tert-butylphenoxy)acetate
• CAS NO: 768378-07-0
• Molecular Weight: 264.365
• Mol File: 768378-07-0.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: tert-butyl 2-(4-tert-butylphenoxy)acetate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 2-(4-tert-butylphenoxy)acetate(768378-07-0)
• EPA Substance Registry System: tert-butyl 2-(4-tert-butylphenoxy)acetate(768378-07-0)

Safety Data

• Hazardous Substances Data: 768378-07-0(Hazardous Substances Data)

Upstream product

• 5292-43-3 bromoacetic acid tert-butyl ester 
• 98-54-4 para-tert-butylphenol 

Downstream Products

• 1435933-32-6 C₂₁H₂₉N₃O₃ 
• 1435933-33-7 C₂₀H₂₆ClN₃O₃ 
• 1798-04-5 (4-tert-butylphenoxy)acetic acid 
• 1435933-28-0 C₁₉H₂₅N₃O₂ 
• 1435933-30-4 C₂₀H₂₇N₃O₂ 
• 1435933-31-5 C₂₀H₂₇N₃O₃ 
• 90734-55-7 (4-tert-butylphenoxy)acetyl chloride 
• 1401223-28-6 N-isopropyl-2-(4-tert-butylphenoxy)-N-((3-(pyridin-3-yl)-1,2,4-oxadiazol-5-yl)methyl)acetamide 

Relevant articles and documents

Synthesis and SAR study of novel 3,3-diphenyl-1,3-dihydroindol-2-one derivatives as potent eIF2·GTP·Met-tRNAiMet ternary complex inhibitors

The growing recognition of inhibition of translation initiation as a new and promising paradigm for mechanism-based anti-cancer therapeutics is driving the development of potent, specific, and druggable inhibitors. The 3,3-diaryloxindoles were recently reported as potential inhibitors of the eIF2·GTP·Met-tRNAiMet ternary complex assembly and 3-{5-tert-butyl-2-hydroxyphenyl}-3-phenyl-1,3-dihydro-2H-indol-2- one #1181 was identified as the prototypic agent of this chemotype. Herein, we report our continuous effort to further develop this chemotype by exploring the structural latitude toward different polar and hydrophobic substitutions. Many of the novel compounds are more potent than the parent compound in the dual luciferase ternary complex reporter assay, activate downstream effectors of reduced ternary complex abundance, and inhibit cancer cell proliferation in the low μM range. Moreover, some of these compounds are decorated with substituents that are known to endow favorable physicochemical properties and as such are good candidates for evaluation in animal models of human cancer.

Discovery of potent transient receptor potential vanilloid 1 antagonists: Design and synthesis of phenoxyacetamide derivatives

We aimed to discover a novel type of transient receptor potential vanilloid 1 (TRPV1) antagonist because such antagonists are possible drug candidates for treating various disorders. We modified the structure of hit compound 7 (human TRPV1 IC50 = 411 nM) and converted its pyrrolidino group to a (hydroxyethyl)methylamino group, which substantially improved inhibitory activity (15d; human TRPV1 IC50 = 33 nM). In addition, 15d ameliorated bladder overactivity in rats in vivo.